Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
Abstract In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer. We report data for clinically prognostic subgroups: liver metastases, progesterone receptor status, tumor gr...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/cf9cf9b9d25d4a93984071353e442e17 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|